$Palantir(PLTR)$ is increasingly becoming an important player in the global AI infrastructure race. But its latest developments highlight two very different sides of the business.
In the United States, its defence technology business is gaining further traction through its collaboration with Anduril Industries and military contracts.
In the United Kingdom, however, Palantir faces a fresh challenge as the government prepares to reopen competition for its NHS data platform.
For investors, this creates an interesting question: Can Palantir’s growing defence business offset the risks of losing major international government contracts?
1. Defence AI could become one of Palantir’s biggest growth drivers
Palantir and Anduril announced their strategic partnership in December 2024, bringing together two companies with complementary defence technologies.
Anduril specialises in autonomous defence systems and battlefield technology, while Palantir provides software for managing large amounts of complex data and deploying AI models.
The idea is to connect information collected from military sensors, vehicles and other battlefield systems with AI platforms that can process information and support operational decisions.
This partnership has become more relevant as governments look for ways to integrate AI into military operations.
There is also a concrete development worth watching.
In September 2026, the US Army moved its TITAN programme into production, awarding a combined $192 million in contracts to Palantir and Anduril.
Palantir received $127 million and will lead overall production, while Anduril received $65 million for hardware and system integration.
This is important because moving from prototypes to production is a meaningful step towards wider operational deployment.
If these systems prove effective and additional orders follow, Palantir could strengthen its position in military software and AI infrastructure.
2. The NHS decision introduces a different kind of risk
While Palantir is expanding its defence business, its position in the UK healthcare market faces uncertainty.
Palantir currently leads the consortium providing the NHS Federated Data Platform, which helps healthcare organisations connect information across different systems.
The platform is intended to improve hospital operations, patient scheduling, discharge planning and the management of healthcare resources.
However, the UK government has decided to launch a new procurement process for the next generation of the platform.
The current arrangement will continue until March 2029, but the government wants to encourage more competition and strengthen domestic technology capabilities.
British companies are preparing to compete, and Palantir may have to defend its position against local technology providers.
This matters because winning government contracts is not just about securing revenue. Long-term relationships can create opportunities to expand into other departments and services.
If Palantir loses the NHS contract in the future, it could affect its ability to expand further across the UK public sector.
However, this is not an immediate loss of business. Palantir still has time to demonstrate the platform’s value and compete for the next contract.
3. Two different markets, two different growth opportunities
The defence and healthcare developments highlight how Palantir’s business model works.
Its software is designed to help organisations combine information from different sources, analyse complex situations and make decisions more efficiently.
That capability can be applied to military operations, hospitals, government departments and commercial businesses.
The advantage is that once a platform becomes deeply integrated into an organisation’s operations, replacing it can be complicated and expensive.
This can create long-term customer relationships and opportunities for additional contracts.
But there is also a risk.
Governments may decide to develop their own systems, use domestic suppliers or move towards competing platforms.
The NHS procurement process demonstrates that even an established supplier cannot assume its position is permanent.
4. What should PLTR investors watch next?
I would focus on three developments.
• US defence contracts: Whether the TITAN programme moves towards additional production orders and whether Palantir secures more military AI deployments.
• UK NHS procurement: Whether Palantir can retain its position when the next-generation platform goes out to tender.
• Commercial AI adoption: Whether businesses continue increasing their use of Palantir’s Artificial Intelligence Platform (AIP), creating revenue beyond government and defence customers.
The commercial business is particularly important because it could reduce the company’s dependence on government contracts over time.
My investment perspective
I see the defence partnership as a longer-term opportunity rather than an entirely new catalyst. The recent TITAN production award provides more tangible evidence of progress.
The NHS situation is more complicated. Losing a major contract would be disappointing, but the new procurement process also gives Palantir an opportunity to demonstrate why its existing platform deserves to remain in place.
One thing investors should not overlook is valuation. Palantir has attracted considerable attention because of its AI exposure and growth potential. However, even a strong business can become a risky investment if its share price already reflects years of future growth.
I would therefore look beyond individual contract announcements and pay attention to revenue growth, operating margins, cash generation and valuation.
Palantir is competing to become an important software provider for governments and businesses. The opportunity is substantial, but competition is increasing on both sides of its business.
The key question is whether Palantir can become essential AI infrastructure for governments worldwide, or whether domestic alternatives will gradually limit its international expansion.
For discussion purposes only.
Comments